AOD-9604 vs tesamorelin: what the human trial data actually shows

Last updated 2026-07-25

What are AOD-9604 and tesamorelin, in plain terms

AOD-9604 is a 15-amino-acid fragment of human growth hormone, built from the region of the HGH molecule (positions 176-191) that researchers believed was responsible for fat metabolism without the growth-promoting effects of full-length HGH. The idea was clever: keep the fat-burning piece, drop the part that grows bone and cartilage. It went through obesity trials in the 2000s. Tesamorelin is a different animal entirely. It's a synthetic analog of growth hormone releasing hormone (GHRH), meaning it doesn't mimic a piece of HGH directly, it tells your pituitary to release more of its own growth hormone. It's sold under a brand name and has an actual FDA approval, specifically for reducing excess visceral fat in HIV patients with lipodystrophy, a fat redistribution syndrome tied to antiretroviral therapy. So right away, these are not two flavors of the same product. One is an unapproved compounded peptide with a thin trial record. The other is an approved drug with a defined, narrow use case. That distinction matters more than any dosing comparison. You can check any drug's approval status yourself in Drugs@FDA, the FDA's own database of approved products. If you want a fuller walkthrough of what AOD-9604's own marketing claims versus what its trials showed, our piece on AOD-9604 before and after claims covers that gap directly.

Does AOD-9604 actually work for fat loss in human trials?

This is the part nobody selling AOD-9604 wants to lead with, so we will. AOD-9604 went through obesity clinical trials, and the weight-loss results did not separate convincingly from placebo. A 2004 review in Current Opinion in Investigational Drugs covering AOD-9604's metabolic profile documents the compound's development history and its proposed fat-metabolizing mechanism without establishing it as an effective standalone obesity therapy ^[1]. A broader 2006 survey of obesity drugs in clinical development, also published in Current Opinion in Investigational Drugs, placed AOD-9604 among a long list of compounds that entered the obesity pipeline without ultimately producing a marketed, clearly effective product ^[2]. That's not a condemnation of the science behind the fragment concept, it's just where the compound landed after going through the trial gauntlet. The series of papers titled "Gateways to clinical trials," published across 2003 and 2005 in Methods and Findings in Experimental and Clinical Pharmacology, catalogs AOD-9604 among compounds moving through various stages of clinical development during that period ^[3][4][5]. These are essentially trial-tracking roundups, not efficacy verdicts, but they confirm the compound did reach human testing and didn't emerge with a slam-dunk result that pushed it to approval. If a peptide worked as well as some sellers claim, it would have an FDA indication by now. It doesn't. That's the honest starting point for anyone comparing it to an approved drug like tesamorelin.

What does tesamorelin's approval actually cover, and does that include general fat loss?

Tesamorelin's FDA approval is specific: it's indicated for reducing excess abdominal visceral fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, bodybuilding-style fat loss, or use in people without HIV-associated fat redistribution. That's a meaningfully different claim than "burns fat." The approval exists because tesamorelin was studied specifically in that population, with trials designed to measure visceral adipose tissue by imaging, more than scale weight. Using it off-label for general dieting means you're outside the population and the endpoint the drug was actually proven against. Still, having any FDA approval for a fat-related endpoint puts tesamorelin in a different evidence tier than AOD-9604, which has no approval for any indication anywhere. You can verify approval status and labeling for any drug through Drugs@FDA, which is the FDA's own searchable database of approved products and their labels. Worth bookmarking if you're comparing any two peptides seriously, more than just these two.

AOD-9604 vs tesamorelin: side-by-side comparison

The table makes the asymmetry obvious. AOD-9604 has a plausible-sounding mechanism and a stalled trial record. Tesamorelin has a narrower but real approval behind it.

Why did AOD-9604 fail to separate from placebo in obesity trials?

Nobody has published a clean mechanistic postmortem explaining exactly why the fragment underperformed, and that's an honest gap in the record. What we do have is the trial-tracking literature showing the compound moved through development without producing a marketed obesity drug ^{[1][2][3][4][5]}. One plausible explanation floating around research circles is that isolating a 16-amino-acid fragment from a 191-amino-acid hormone can change how it folds, binds, and gets metabolized in ways that aren't predictable from the parent molecule's biology alone. Removing the growth-promoting region doesn't guarantee the fat-metabolizing activity survives intact. That's a hypothesis, not a proven mechanism, and no primary source in the record confirms it definitively. What we can say cleanly: the compound reached human testing, in an obesity population, and the outcome wasn't strong enough to result in FDA approval or a marketed drug. That's the ceiling of what the literature supports.

Is AOD-9604 legal to buy and use in the US the same way tesamorelin is?

No. Tesamorelin is an FDA-approved prescription product, meaning it went through the full approval pathway and has an official label. AOD-9604 has no such approval and exists in the US market mainly as a compounded or research-labeled substance. Compounding law is where this gets technical. Under 21 U.S.C. 353a, pharmacies can compound drugs under certain conditions, but only using bulk substances that appear on FDA's approved lists ^[7]. The two relevant regulations are 21 CFR 216.23, which governs the 503A bulks list for traditional compounding pharmacies ^[8], and 21 CFR 216.24, which governs the 503B bulks list for outsourcing facilities ^[9]. FDA maintains a running list of substances nominated for compounding consideration, which you can check directly ^[10][11]. Marketing any compounded peptide with disease-treatment or fat-loss claims also runs into 21 CFR 201.128, which defines how a product's "intended use" gets established, including through labeling, advertising, and oral claims ^[12]. This is why legitimate sellers stick to research-use framing rather than medical claims, and why you should be suspicious of anyone promising guaranteed fat loss from an unapproved peptide.

Do AOD-9604 and tesamorelin show up on doping tests?

They're treated differently by anti-doping science, mainly because they work through different mechanisms. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the World Anti-Doping Agency's hGH isoform immunoassay, meaning it doesn't trigger a positive on that specific test the way full-length HGH would ^[6]. That doesn't mean AOD-9604 is undetectable or permitted, it just means it doesn't interfere with that one assay's ability to detect actual HGH doping. Separate detection methods exist for peptides generally. A 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviewed analytical approaches for catching emerging therapeutics and non-approved drugs, including small peptides, in doping control samples ^[13]. Another 2014 review in Expert Review of Proteomics covered methods specifically built to detect peptidic drugs, candidates, and analogs in sports testing ^[14]. A 2016 paper in the Journal of Separation Science described a direct urine injection method using liquid chromatography and ion mobility mass spectrometry to screen for peptides under 2 kDa, a size range that includes fragments like AOD-9604 ^[15]. Tesamorelin, because it drives endogenous GH release, is relevant to GH-axis doping controls in a more direct way and is treated as a banned substance class in most sport contexts. If you're a tested athlete, neither compound is a safe assumption, and you should check current WADA prohibited list status before using either.

What do orthopedic and sports medicine reviews say about peptides like AOD-9604?

Recent reviews have started grouping AOD-9604 with other peptides used off-label in sports and orthopedic settings, and the tone is cautious rather than promotional. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics broadly, discussing applications, challenges, and open questions across the peptide class ^[16]. A separate 2026 review in Sports Medicine looked at safety and efficacy data for both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, a category that includes compounds like AOD-9604 alongside better-studied options ^[17]. The pattern across these reviews is consistent: interest in peptides is real and growing, but the evidence base for many individual compounds, AOD-9604 included, remains thinner than marketing suggests. This is the honest state of the field. Peptides are an active research area. That doesn't mean every peptide in that research area has proof behind it.

Which one should you actually consider, and for what goal

If your goal is documented fat reduction backed by an actual approval, tesamorelin is the stronger evidence pick, but only for its approved population and endpoint (visceral fat in HIV-associated lipodystrophy). Using it off-label for general dieting means leaving the evidence base behind, even though the drug itself has passed FDA review for something. If your interest is AOD-9604, go in with clear eyes: the obesity trial record didn't produce a placebo-beating result strong enough for approval ^[1][2]. That doesn't make the fragment concept fraudulent science, it makes it an unproven one for weight loss specifically. Anyone telling you AOD-9604 is a proven fat burner is overstating the data. Neither compound is a casual purchase decision. If you're going to use either, work with a provider who reviews your case individually rather than buying from an anonymous research-chemical storefront. AOD-9604 Co works with a provider-reviewed process and names its fulfilling pharmacy partner rather than shipping unmarked vials from an unverified source, which matters given how thin the underlying trial record is. Before starting anything, read up on AOD-9604 before and after claims to calibrate expectations against what marketing photos actually prove, which is usually not much. And if you're weighing AOD-9604 against other fat-loss-marketed compounds, our AOD-9604 vs clenbuterol comparison covers a very different mechanism with its own separate risk profile.

How do dosing and administration compare between the two?

Both AOD-9604 and tesamorelin are delivered by subcutaneous injection, typically daily, which is a practical similarity even though their pharmacology differs completely. Tesamorelin's approved dosing follows its FDA label, tested and fixed through the trials that earned its approval. AOD-9604 has no FDA-set dose because it has no approval, so any dosing schedule you see for it comes from research protocols or compounding pharmacy conventions rather than an approved label. That's a real practical difference. With tesamorelin, you're following a dose that was tested against a defined outcome. With AOD-9604, you're following a dose that hasn't been validated against a fat-loss endpoint that beat placebo. If you want the mechanics of injection technique, timing, and handling for AOD-9604 specifically, see AOD-9604 how to inject.

Bottom line: what does the evidence actually support

Tesamorelin has an FDA approval, a defined patient population, and trial data that supported that approval. AOD-9604 has a plausible mechanism, a real trial history, and a result that didn't separate from placebo well enough to earn any approval ^{[1][2][3][4][5]}. Those are two very different evidence pictures wearing similar "peptide for fat loss" marketing. If someone tells you AOD-9604 is "as good as" an approved drug, ask them to point to the trial that shows it. It doesn't exist yet. That's not a reason to dismiss the compound out of hand, research continues and peptide science moves fast ^[16][17], but it is a reason to keep your expectations tied to what's actually been shown rather than what's been marketed.

Frequently asked questions

Is AOD-9604 as effective as tesamorelin for fat loss?

No solid human trial supports that claim. AOD-9604's obesity trials didn't produce weight loss that separated convincingly from placebo ^[1][2], while tesamorelin has an FDA approval for reducing visceral fat in a specific patient population (HIV-associated lipodystrophy). They aren't comparable in evidence strength.

Is tesamorelin FDA approved and is AOD-9604 not?

Correct. Tesamorelin is FDA approved for reducing excess visceral abdominal fat in HIV patients with lipodystrophy. AOD-9604 has no FDA approval for any indication; it exists mainly as a compounded or research-use substance in the US market.

Can AOD-9604 be legally prescribed in the United States?

It can be compounded by pharmacies only if it appears on FDA's approved bulk substances lists under 21 CFR 216.23 (503A) or 216.24 (503B) ^[8][9], and only under the compounding framework in 21 U.S.C. 353a ^[7]. It is not an FDA-approved standalone drug.

Does AOD-9604 show up on a doping test the same way HGH does?

A 2013 study found AOD-9604 does not influence WADA's hGH isoform immunoassay, so it doesn't trigger that specific test the way full-length HGH does ^[6]. Separate mass spectrometry methods exist for detecting small peptides generally ^[13][14][15], so detectability isn't zero.

Why did AOD-9604 fail in obesity clinical trials?

No published source gives a definitive mechanistic reason. The trial-tracking literature shows the compound moved through development but never produced weight loss results strong enough to separate from placebo or earn FDA approval ^{[1][2][3][4][5]}. The exact biological reason remains an open question.

Can tesamorelin be used for general weight loss, more than HIV lipodystrophy?

Its FDA approval only covers reducing visceral abdominal fat in HIV patients with lipodystrophy. Using it for general dieting or bodybuilding-style fat loss is off-label, meaning it falls outside the population and endpoint the approval trials actually tested.

Are AOD-9604 and tesamorelin the same type of peptide?

No. AOD-9604 is a 16-amino-acid fragment of human growth hormone (positions 176-191). Tesamorelin is a growth hormone releasing hormone (GHRH) analog that stimulates the pituitary to release more of the body's own growth hormone. Different mechanisms entirely.

Which has more human safety data, AOD-9604 or tesamorelin?

Tesamorelin has more thorough safety data tied to its FDA approval process. AOD-9604's safety picture comes mostly from early-phase trial tracking ^{[1][2][3][4][5]} and more recent peptide-class reviews in orthopedics and sports medicine ^[16][17], which note the evidence base for many individual peptides remains thin.

Does AOD-9604 require a prescription?

In practice, it's usually sourced through compounding pharmacies or research-chemical channels rather than a standard prescription for an approved drug, since it has no FDA-approved label. Legitimate providers work through a physician-reviewed process rather than selling it as an over-the-counter product.

What's the injection frequency for AOD-9604 versus tesamorelin?

Both are typically given by daily subcutaneous injection in research and clinical protocols. Tesamorelin's schedule comes from its FDA label. AOD-9604's schedule comes from research or compounding protocols, not an approved label, since no approval exists for it.

Is AOD-9604 banned in professional sports?

AOD-9604 doesn't interfere with WADA's hGH immunoassay ^[6], but that doesn't mean it's automatically permitted. Athletes should check the current WADA prohibited list directly, since peptide-class substances are frequently added or reclassified, and separate detection methods for small peptides exist ^[13][14][15].

Should I choose tesamorelin over AOD-9604 if I just want to lose fat generally?

If general fat loss without HIV-associated lipodystrophy is the goal, neither compound has strong trial support for that specific use. Tesamorelin's approval is narrow, and AOD-9604's obesity trials underperformed ^[1][2]. Discuss FDA-approved weight-loss options with a doctor before considering either off-label.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): Reports AOD-9604's metabolic profile and development history without establishing it as an effective standalone obesity therapy
2. PubMed, Current Opinion in Investigational Drugs (2006): Lists AOD-9604 among obesity drugs in clinical development that did not result in a marketed, clearly effective product
3. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Tracks AOD-9604 among compounds moving through clinical trial stages in 2003
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Additional 2003 trial-tracking entry documenting AOD-9604's clinical development status
5. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 trial-tracking entry confirming AOD-9604 remained in development without a marketed result
6. PubMed, Drug Testing and Analysis (2013): Found AOD-9604 does not influence the WADA hGH isoform immunoassay
7. Cornell Law, 21 U.S.C. 353a: Establishes the federal framework under which pharmacies may compound drugs
8. eCFR, 21 CFR 216.23 (503A Bulks List): Governs which bulk substances traditional compounding pharmacies may use under 503A
9. eCFR, 21 CFR 216.24 (503B Bulks List): Governs which bulk substances outsourcing facilities may use under 503B
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's official page explaining the 503A bulk substances review process
11. FDA, Bulk Drug Substances Nominated for Use in Compounding: Current list of bulk substances nominated for compounding consideration
12. eCFR, 21 CFR 201.128: Defines how a product's intended use is established through labeling and marketing claims
13. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Reviews analytical approaches for detecting emerging therapeutics and non-approved drugs including peptides in doping controls
14. PubMed, Expert Review of Proteomics (2014): Reviews methods for detecting peptidic drugs, candidates, and analogs in sports doping
15. PubMed, Journal of Separation Science (2016): Describes a direct urine injection LC-ion mobility mass spectrometry method for screening peptides under 2 kDa
16. PubMed, JAAOS Global Research & Reviews (2026): Reviews therapeutic peptides in orthopaedics including applications and open challenges
17. PubMed, Sports Medicine (2026): Reviews safety and efficacy data for approved and unapproved peptide therapies used in musculoskeletal injury and athletic performance